The company said it completed its acquisition of Axonics, Inc. on November 15, 2024. The purchase price is $71 in cash per share, and Axonics is a medical technology company that develops and commercializes devices to treat urinary and bowel dysfunction.

8-KOther EventsFiled Nov 15, 2024Period of report Nov 15, 2024Summary published (UTC) Oct 25, 2026

Key points

AI summary

The company said it completed its acquisition of Axonics, Inc. on November 15, 2024. The purchase price is $71 in cash per share, and Axonics is a medical technology company that develops and commercializes devices to treat urinary and bowel dysfunction.
The company said the $71 per share cash purchase price represents an equity value of $3.7 billion and an enterprise value of $3.3 billion, net of cash and short-term investments acquired.
Boston Scientific said it expects the transaction to be immaterial to adjusted earnings per share in 2024 and 2025 and accretive thereafter. It said that on a GAAP basis, it expects the deal to be less accretive, or more dilutive, due to amortization expense and acquisition-related charges.
Citing Urology president Meghan Scanlon, the company said the Axonics product portfolio will let it expand into sacral neuromodulation, a high-growth adjacency for its Urology business.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Boston Scientific Completes Axonics Acquisition and Per-Share Purchase Price

The company said it completed its acquisition of Axonics, Inc. on November 15, 2024. The purchase price is $71 in cash per share, and Axonics is a medical technology company that develops and commercializes devices to treat urinary and bowel dysfunction.

Source · Based on the filing body and exhibits

Equity and Enterprise Value of Axonics Acquisition

The company said the $71 per share cash purchase price represents an equity value of $3.7 billion and an enterprise value of $3.3 billion, net of cash and short-term investments acquired.

Source · Based on the filing body and exhibits

Expected Impact of Acquisition on Adjusted EPS

Boston Scientific said it expects the transaction to be immaterial to adjusted earnings per share in 2024 and 2025 and accretive thereafter. It said that on a GAAP basis, it expects the deal to be less accretive, or more dilutive, due to amortization expense and acquisition-related charges.

Source · Based on the filing body and exhibits

Business Area Expanded by Axonics Acquisition

Citing Urology president Meghan Scanlon, the company said the Axonics product portfolio will let it expand into sacral neuromodulation, a high-growth adjacency for its Urology business.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.